Research programme: anticancer nanotherapeutics - Merrimack Pharmaceuticals

Drug Profile

Research programme: anticancer nanotherapeutics - Merrimack Pharmaceuticals

Alternative Names: MM 310

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Merrimack Pharmaceuticals
  • Class
  • Mechanism of Action Eph family receptor modulators; EphA2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Jan 2017 Merrimack plans a phase I trial for Cancer in 2017
  • 21 Apr 2016 Pharmacokinetics, pharmacodynamics, adverse events and efficacy data from a preclinical study presented at the 107th annual American Association for Cancer Research meeting (AACR 2016) (9194727; 3191412)
  • 10 Dec 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top